





Key Particulars of the QIO					Major Products of the Company									
Ticker			AMPL		Al-Madina Pharmaceuticals Limited was incorporated on 27th July, 2006 as a Private Limited Company and subsequently converted into a Public Limited company in 30th November 2021. The company is engaged in the manufacturing, buying, selling, refinement, import, export or otherwise of pharmaceutical products and preparations, patent drugs and proprietary articles of all kinds. It currently has more than 150 products of animal health products in production such as antibacterial drugs, nutritional products, poultry vaccines etc and 70 plus essential pharma products anti-bacterial drugs, anti-fungal drugs, gastro-intestinal drugs etc. The chairman of the company Md. Billal Hossain is a prominent businessman who has over 20 years of experience in the pharmaceutical industry and also has interests in numerous companies such as Royal Footwear Ltd, Smart shoes Ltd, Royal Toiletries Ltd, Marigold Real Estate Ltd, Marigold Associate Ltd etc.									
Face Value (Tk.)			10											
No. of Share (QIO)			5,000,000											
No. of Pre-QIO Share			15,400,000											
No. of Post-QIO Share			20,400,000											
Issue Size (Offer Price) (Tk)			10											
Pre-QIO Paid-up Capital (TK)			154,000,000											
Post-QIO Paid Up (Tk)			204,000,000											
Authorized Capital (Tk)			300,000,000											
No. of Free Float Shares on Debut			5,000,000											
EPS (Sep, 2022)			0.45											
NAVPs With Revaluation (Sep, 2022)			22.10											
NAVPs Without Revaluation (Sep, 2022)			13.08											
PE at Tk 10 (Post-QIO)			5.55											
Name of Sponsors and Directors and Key Personnel					Use of the Proceeds of QIO									
Name		Position		Post QIO %		Particulars		Amount		%				
Md. Zakir Hossain Patwari		MD		31.43%		Business Expansion		30,800,000		61.6%				
Md. Billal Hossain		Chairman		20.96%		Loan Repayment		16,700,000		33.4%				
Md. Kamrul Alam		Director		17.46%		QIO Expenses		2,500,000		5.0%				
Total				69.85%		Total		50,000,000		100%				
Financing of QIO Fund					Implication Schedule of QIO Proceeds									
Particulars		%	No. of Ordinary Shares		Offer Price	Issue Amount (Taka)		Particulars		Approximate period of project completion & commercial operation				
Eligible investor (EI)		100 %	5,000,000		10	50,000,000		Business Expansion		Within 24 months after receiving QIO fund				
History of Capital Raising					Loan Re-Payments		Immediately after receiving QIO fund		Financial Indicators					
Date of Allotment		Mode of Allotment (No. of Shares)			Issue Price (Tk.)		Paid Up Capital		Ratio	2022	2021	2020	2019	2018
		In cash	Other	Bonus					ROA	3.87%	7.26%	8.26%	-1.29%	-2.48%
02.08.2006		300,000	-	-	10		3,000,000		ROE	5.92%	8.06%	51.09%	10.37%	15.03%
16.06.2021		-	8,500,000	-			85,000,000		Net Operating Cash Flow per Share	-0.55	65.93	250.22	36.19	26.97
28.06.2021		4,000,000	-	-			40,000,000		Operating Margin	6.91%	7.84%	7.97%	2.24%	-0.50%
31.07.2021		2,200,000	-	-			22,000,000		Net Profit Margin	2.95%	4.17%	2.82%	-0.45%	-1.10%
30.08.2021		400,000	-	-			4,000,000							
Total							154,000,000							

**Revenue (BDT in mn)****Operating Profit Margin vs Net Profit Margin****Net Profit after tax (BDT in mn)****Return on Assets & Return on Equity****Shareholding Structure**

Category	Post IPO %
Directors & Sponsors	69.85%
Individual Shareholders	5.15%
Institutional Shareholder	0.49%
Qualified Investor (QI)	24.51%
Total	100%

**Dividends Declaration**

Year	2021	2020	2019	2018	2017
Cash	Nil	Nil	Nil	Nil	Nil
Stock	Nil	Nil	Nil	Nil	Nil

**Prepared by**

Syed Reazul Haque	Research Analyst
Shakawat Hossain	Research Analyst
Samin Farhan Chowdhury	Research Analyst

**Disclaimer**

This Document/Report has been prepared and issued by Prime Bank Investment Limited on the basis of the public information available in the market, internally developed data and other sources believed to be reliable. Whilst all reasonable care has been taken to ensure that the facts and information stated in the Documents are accurate as on the date mentioned herein. If any person takes any action relying on this Document, shall be responsible solely by himself/herself/themselves for the consequences thereof any claim or demand for such consequences shall be rejected outright by PBIL or by any court of law.

**Price relative to different prices**

Price	10	12	14	16	18	20
PE	5.56	6.66	7.77	8.88	10	11.11

**Capacity Utilization**

Major Products	Unit	Production Capacity	Actual Production (AVG)	Capacity Utilization
Tablet	Pcs	436,500,000	261,900,000	60%
Capsule	Pcs	167,616,000	92,188,800	55%
Liquid	Litre	291,000	203,700	70%
Liquid (External)	Bottle	2,328,000	232,800	10%
Powder	Kgs	145,500	87,300	60%
Bolus	Pcs	29,100,000	14,550,000	50%
Cream, Gel, Ointment,	Tube	2,328,000	1,629,600	70%
PFS	Bottle	2,328,000	93,120	40%

**Other QIO Details****Issue Date of Prospectus:** March 28, 2023**Year End:** June**Issue Manager:** Prime Bank Investment Ltd**Auditor:** Shiraz Khan Basak & Co